Další formáty:
BibTeX
LaTeX
RIS
@proceedings{870993, author = {Šimara, Pavel and Grant, Steven and Holyoake, Tessa and Pellicano, Francesca}, booktitle = {ESH: CHRONIC MYELOID LEUKEMIA - Biological Basis of Therapy.}, keywords = {BMS-214662, CML}, language = {eng}, title = {MEK inhibition enhances BMS-214662-induced apoptosis in primitive CD34+ CML stem/progenitor cells.}, url = {http://www.esh.org}, year = {2009} }
TY - CONF ID - 870993 AU - Šimara, Pavel - Grant, Steven - Holyoake, Tessa - Pellicano, Francesca PY - 2009 TI - MEK inhibition enhances BMS-214662-induced apoptosis in primitive CD34+ CML stem/progenitor cells. KW - BMS-214662, CML UR - http://www.esh.org N2 - In presented work we have used the FTI in combination with MEK inhibitor PD184352 to increase the effect of FTI BMS-214662 in both proliferating and quiescent CML stem/progenitor cells. We have shown that MEK inhibitor PD184352 increases the apoptotic effect of FTI BMS-214662 in the K562 cell line as well as in CD34+ CML cells. We observed increased Annexin V and active Caspase-3 levels. We confirmed the cleavage of Caspase-3 substrate PARP. Apoptosis acts via the intrinsic pathway, as decreased mitochondrial membrane potential and downregulation of the mitochondrial anti-apoptotic protein MCL-1 was determined. Our results suggest that the RAS-MEK pathway is involved in BMS-214662 and PD184352 induced apoptosis and Caspases play a role in apoptotic signal transduction. Our data reveal that targeting of the MEK-ERK pathway sensitises CD34+ CML stem/progenitor cells treated with FTI BMS-214662. This study suggests that combination treatment may improve the ability of BMS-214662 to selectively target quiescent leukaemia stem/progenitor cells, which are insensitive to TKI treatment and responsible for persistence and relapse of disease. ER -
ŠIMARA, Pavel, Steven GRANT, Tessa HOLYOAKE a Francesca PELLICANO. MEK inhibition enhances BMS-214662-induced apoptosis in primitive CD34+ CML stem/progenitor cells. In \textit{ESH: CHRONIC MYELOID LEUKEMIA - Biological Basis of Therapy.}. 2009.
|